Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | FABP4 | P15090 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | STAT3 | P40763 | 13/20 | 0.72 |
| ▸ | MGAM | O43451 | 1/20 | 0.55 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Andrographolide SCHEMBL19704806 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL12777642 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL15263160 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL62262 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL12206780 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL24806666 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL12750463 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL3668454 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL20828610 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL62263 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CROSSBETA BIOSCIENCES B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CROSSBETA BIOSCIENCES B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267948-A1 | Croos-B Structure Binding Compounds | CACYBP, TBCB, MYCBP | NR1H4 2670/4885TP53 2046/4885CYP3A4 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.